Skip to content

Acadia Pharmaceuticals ACAD Deferred Tax Assets

Deferred Tax Assets at other companies

Biogen logo
BiogenBIIB
$483.5M+263%
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
$381.4M-23.6%
Catalyst Pharmaceutical logo
Catalyst PharmaceuticalCPRX
$55.11M+14.3%
PTC Therapeutics logo
PTC TherapeuticsPTCT
-$10K-600%
TG Therapeutics logo
TG TherapeuticsTGTX
$344.14M
Xenon Pharmaceuticals logo
Xenon PharmaceuticalsXENE
$12.42M+14.1%

Other financials

Income statement

See full
Revenue$268.1M+9.7%
Gross profit$243.3M+8.6%
Operating income-$4.6M-124%
Net income$3.6M-80.8%
EPS (diluted)$0.02-81.8%

Balance sheet

See full
Cash & equivalents$282.2M+29.6%
Total debt$50.8M-9.3%
Total equity$1.2B+63.1%
Total assets$1.6B+41.8%

Cash flow

See full
Operating cash flow$34.0M+67.2%
CapEx$5.2M
Free cash flow$28.8M+41.6%

Valuation

See full
Market cap$3.87B+37.0%

Profitability

See full
Gross margin91.5%-0.6pp
Operating margin7.4%-16.2pp
Net margin34.3%+11.3pp
FCF margin18.9%

Returns & leverage

See full
Return on equity37.3%+0.1pp
Debt / equity0.0×
Current ratio3.6×+0.7×

Where this comes from

Reported directly by Acadia Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:DeferredIncomeTaxAssetsNet.

The official record: Acadia Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Acadia Pharmaceuticals's deferred tax assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Acadia Pharmaceuticals's deferred tax assets?
Acadia Pharmaceuticals (ACAD) reported deferred tax assets of $249.62M in Q1 2026.
What does deferred tax assets mean?
Future tax benefits from temporary differences, net operating loss carryforwards, and tax credit carryforwards that will reduce future tax payments.